Cargando…
Core harm outcome sets developed by drug are needed to allow informed risk-benefit decision making
Autores principales: | Cornelius, Victoria, Liu, Kun, Peacock, Janet, Sauzet, Odile |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660287/ http://dx.doi.org/10.1186/1745-6215-16-S2-P55 |
Ejemplares similares
-
Usability and consistency of harm information in drug product descriptions: a matched comparison of data between the United States (US) and Europe
por: Cornelius, Victoria R, et al.
Publicado: (2015) -
Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents
por: Cornelius, Victoria R, et al.
Publicado: (2016) -
Making core outcomes more clinically meaningful: 2-for-the-price-of-1 with a distributional approach
por: Peacock, Janet L, et al.
Publicado: (2015) -
Making continuous outcomes meaningful to clinicians
por: Peacock, Janet L, et al.
Publicado: (2011) -
Binomial outcomes in dataset with some clusters of size two: can the dependence of twins be accounted for? A simulation study comparing the reliability of statistical methods based on a dataset of preterm infants
por: Sauzet, Odile, et al.
Publicado: (2017)